Medical/Pharmaceuticals
AffaMed Therapeutics and SIFI Announce Joint Venture to Serve Greater China Market
SHANGHAI, March 31, 2021 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a global clinical-stage biopharmaceutical company dedicated to addressing critical unmet patient need in ophthalmic, neurological and psychiatric disorders, and SIFI S.p.A. ("SIFI"), a leading international ophthalmic com...
2021-03-31 19:30
2458
Future Health: Innovative Health Around the World
LONDON, March 31, 2021 /PRNewswire/ -- It started with the UK but the renowned organisers of Future Health Innovation have recently announced the launch of a full series of digital events - the Health Week Series. Concentrating on key markets around the world, there will be a Summer and Autumn ev...
2021-03-31 18:36
2284
CStone Announces China NMPA New Drug Approval of Precision Therapy AYVAKIT® (avapritinib) for the Treatment of Adults with Unresectable or Metastatic PDGFRA Exon 18 Mutant Gastrointestinal Stromal Tumor
SUZHOU, China, March 31, 2021 /PRNewswire/ -- CStone Pharmaceuticals (CStone, HKEX: 2616), a leading biopharmaceutical company focused on developing and commercializing innovative immuno-oncology therapies and precision medicines, today announces that the National Medical Products Administration ...
2021-03-31 18:20
7230
Evive Biotech Submits Biologics License Application to US FDA for Ryzneuta(TM)
* BLA submission to the U.S. FDA follows successful conclusion of Evive's Global Phase III Clinical Trial for chemotherapy-induced neutropenia in breast cancer patients. * Evive is the first Chinese biologics company to advance a novel biologic product from pre-clinical studies to a complet...
2021-03-31 11:26
2839
Cigna Study Shows Uncertainty about the Future as Leading Cause of Stress
HONG KONG, March 31, 2021 /PRNewswire/ -- Cigna Hong Kong today released the Hong Kong findings of the latest edition of its Cigna COVID-19 Global Impact Study. As part of Cigna's annual 360 Well-Being Survey, this research is the fourth in a series of studies to better understand the impact of t...
2021-03-31 11:09
3839
Everest Medicines Announces China NMPA Approval of Clinical Trial Application to Evaluate Trodelvy® in a Phase 2 Basket Trial for a Variety of Cancers with High TROP-2 Expression
SHANGHAI, March 31, 2021 /PRNewswire/ -- Everest Medicines
2021-03-31 10:27
4260
Menarini Silicon Biosystems launches CELLSEARCH® Circulating Multiple Myeloma Cells Assay, a new non-invasive test to monitor disease status in clinical research studies
BOLOGNA, Italy and HUNTINGDON VALLEY, Pa., March 31, 2021 /PRNewswire/ -- Menarini Silicon Biosystems, a pioneer of liquid biopsy and single cell technologies, announced today the launch of a new assay to meet the needs of pharma companies, CROs, clinicians and research scientists working on mult...
2021-03-31 10:00
5662
3SBio announces 2020 annual results, tapping integrated platform advantages for steady growth
SHANGHAI, March 30, 2021 /PRNewswire/ -- Chinese leading biopharmaceutical company 3SBio (01530.HK) today unveiled its 2020 full-year results. The Company maintained stable profitability despite the huge challenge amid the COVID-19 pandemic, while ushering in new milestones. It once again demonst...
2021-03-31 09:11
3795
ImmuneOncia and 3D Medicines Signed Exclusive License Agreement to Develop, Manufacture and Commercialize IMC-002 in Greater China
* 3D Medicines to Lead the Manufacture, Clinical Development and Commercialization of IMC-002 for Oncology indications inGreater China * ImmuneOncia to Receive potentially up to $470.5M including $8M Upfront, and Future Development and Commercial Milestone Payments, plus Tiered Royalties on N...
2021-03-31 09:00
2448
Innovent Announces Parsaclisib (IBI376) was Granted Breakthrough Therapy Designation by the NMPA for the Treatment of Relapsed/Refractory Follicular Lymphoma
SAN FRANCISCO and SUZHOU, China, March 31, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major disea...
2021-03-31 08:00
4641
Viva Biotech Announced 2020 Annual Results
The Group's Revenue Surged by 115.7% YoY Revenue from the CFS Business Increased Significantly by 146.3% YoY Establish One-stop Service Platform for Novel Drug Discovery and Production via Internal Growth and External Expansion Financial Highlights of the year ended December 31, 2020: * Reve...
2021-03-31 07:03
4012
binx health Receives FDA CLIA Waiver for Chlamydia and Gonorrhea Test, Expanding Critical Access to Single-Visit Diagnoses
First ever 30-minute, CLIA-waived, molecular PCR Test for CT/NG now available for OBGYN, physician offices and retail settings holding certificates of waiver BOSTON, March 31, 2021 /PRNewswire/ -- binx health, a population health technology company that provides convenient healthcare solutions, a...
2021-03-31 06:11
2274
European Commission Approves mAbxience's Bevacizumab For The Treatment Of Certain Types Of Cancer
mAbxience, a global fully-fledged biotech company, with over a decade of experience in the development, manufacture and commercialization of biopharmaceuticals, is expanding patient access to biological treatments throughoutEurope. MADRID, March 31, 2021 /PRNewswire/ -- On 31 March 2021, the Eur...
2021-03-31 05:30
10804
Ajinomoto Bio-Pharma Services Expands Manufacturing Agreement with AstraZeneca to Include Drug Product Manufacturing
WETTEREN, Belgium, March 31, 2021 /PRNewswire/ -- Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of biopharmaceutical contract development and manufacturing services, is pleased to announce a manufacturing agreement expansion with AstraZeneca to include drug product manufact...
2021-03-31 01:04
1805
WuXi AppTec Reports Strong 2020 Annual Results
Revenue Up 28.5% Year-over-Year to RMB16,535 Million Net Profit Attributable to Owners of the Company Up 59.6% Year-over-Year to RMB2,960 Million Diluted EPS Up 56.3% Year-over-Year to RMB1.25 Adjusted Non-IFRS Net Profit Attributable to Owners of the Company Up 48.1% Year-over-Year toRMB3,565 Mil...
2021-03-30 21:10
3974
Innovent Announced Financial Results for Full Year Ended December 31, 2020 and Corporate Progress
SAN FRANCISCO and SUZHOU, China, March 30, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major disea...
2021-03-30 20:52
4622
Fosun International Announces 2020 Annual Results: Total Revenue Amounted to RMB136.6 Billion, Gathering Strength to Fuel Growth
2020 Annual Results Summary and Recent Highlights: * Total revenue amounted to RMB136.6 billion. Net profit attributable to owners of the parent wasRMB8.02 billion. Industrial operating profit reached RMB8.15 billion. * Global collaboration has been conducted to develop COVID-19 mRNA va...
2021-03-30 20:03
8388
AffaMed Therapeutics Announces Completion of over US$170 Million Series B Financing Led by Lake Bleu Capital to Further Development of Ophthalmic and Neuroscience Pipeline
SHANGHAI, March 30, 2021 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a global clinical-stage biopharmaceutical company dedicated to addressing critical unmet patient need in ophthalmic, neurological and psychiatric disorders, today announced the completion of over US$170 million in Series B...
2021-03-30 19:30
2015
GemVax's highly promising Phase II Alzheimer's disease clinical trial results targeting telomerase published in prestigious Alzheimer's Research & Therapy' journal
SEOUL, South Korea, March 30, 2021 /PRNewswire/ -- GemVax & KAEL Co., Ltd. (Korea: 082270)("GemVax") has announced that a paper on GV1001, a novel Alzheimer's treatment based on telomerase modification, was published onMarch 26 th in the SCI-grade international journal 'Alzheimer's Research & Ther...
2021-03-30 19:21
3906
Instylla Announces Enrollment of Initial Patients in the Embrace™ Hydrogel Embolic System Global Randomized Multi-Center Clinical Trial
Pivotal study to evaluate the use of novel liquid embolic versus standard of care in treating malignant and benign hypervascular tumors BEDFORD, Mass., March 30, 2021 /PRNewswire/ -- Instylla, Inc., a privately held company developing next-generation liquid embolics for peripheral vascular embol...
2021-03-30 19:02
1207
Week's Top Stories
Most Reposted
Nine Years of Impact: JULO Disburses USD 1.7 Billion in Digital Financing Across Indonesia
[Picked up by 297 media titles]
2025-12-23 14:23
ABL Bio Receives Upfront Payment for License, Research and Collaboration Agreement for Grabody Platform and Equity Investment from Lilly
[Picked up by 277 media titles]
2025-12-26 12:55Fijian and Chinese Scholars Gather to Discuss Bilateral Friendship and the Outlook for APEC 2026
[Picked up by 264 media titles]
2025-12-22 15:56
"Nihao China" App Launches as an All-in-One Solution for International Visitors
[Picked up by 253 media titles]
2025-12-24 17:54Sobot Shines in G2 Winter 2026: A New Benchmark in AI Customer Service
[Picked up by 252 media titles]
2025-12-24 10:00